Granules India Limited recently announced that it is acquiring Senn Chemicals AG, a Swiss-based CDMO specializing in peptides.
Senn develops and manufactures Peptides and peptides-based applications for its global customers, providing contract research, development, and manufacturing services.
The closing of the acquisition is subject to certain conditions. The closing is expected to occur in the first half of 2025, the company said.
Senn’s expertise in Liquid-Phase Peptide Synthesis
The company said the acquisition brings Senn’s expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), along with a strong CDMO business and established customer relationships, including innovators and brand owners across the Pharmaceutical, Cosmetic, Amino Acid Derivatives (AAD), and theragnostic segments.
Senn’s manufacturing facility is certified under ISO 9001:2015 and is regularly inspected and approved for cGMP production by Swissmedic.
Under the Mutual Recognition Agreement (MRA) between Swissmedic and the U.S. Food and Drug Administration (FDA), cGMP inspections conducted by Swissmedic are recognized by the FDA, it said.
Aligning with Granules’ growth strategy
This acquisition enables Granules’ to acquire capabilities into high-growth peptide-based therapeutics. The acquisition aligns with Granules’ vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market, including GLP-1 receptor agonists and other next-generation therapeutics.
Granules and Senn have been developing two GLP-1-based APIs, and both projects are progressing well, and more peptide-based APIs are planned to be added to the portfolio, to be developed using Senn’s R&D capabilities.
Granules enter into CDMO segments
The acquisition marks Granules’ foray into CDMO segments, leveraging Senn’s existing CDMO business and customer relationships on the back of its R&D and manufacturing platform.
The company will leverage Senn’s European presence and innovation-driven peptide platform to accelerate its CDMO expansion and meet the fast-growing demand for Amino Acid derivatives (AAD), peptide fragments, and peptide-based therapeutics.
Senn presence in Europe, provides access to a skilled R&D talent pool and regulated market clients, further strengthening Granules’ global footprint.
By integrating Senn’s capabilities with Granules’ expertise in large-scale, cost-efficient manufacturing, Granules aims to become a key player in the development and manufacturing of peptide-based applications across the Pharmaceutical, cosmetic, and therapeutic segments industries, spanning the entire value chain from AADs and Peptide fragments to peptide-based active ingredients.
Leadership comments
Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, of Granules India, said “The acquisition of Senn Chemicals AG marks a significant milestone in Granules’ strategic growth journey. By entering the rapidly growing peptide therapeutics segment and acquiring CDMO capabilities, we are expanding into next-generation therapeutics that align with our commitment to innovation and affordability.”
“Senn’s expertise in peptide synthesis, coupled with our large-scale, cost-efficient manufacturing capabilities, positions us to deliver high-quality peptide-based solutions globally,” Chigurupati added.
Dr. Rico Wiedenbruch, Chairman, of Senn Chemicals AG, said “We are excited to join forces with Granules India, a company that shares our commitment to scientific excellence and customer-centric innovation. With Granules’ scale, operational efficiency, and global reach in the pharmaceuticals industry, we see strategic fit and tremendous potential to accelerate our growth and expand our capabilities in rapidly growing peptide therapeutics.”
Related:-Â 25 Great Business Ideas for Entrepreneurs 2025
Related:- How To Start A Business When You Have No Money
Related:-Â Difference Between Cash and Profit 2024
Follow  Startupcolleges on Facebook, Instagram, and Twitter, for the latest updates from the startup ecosystem. Subscribe to our YouTube Channel for more entrepreneurship, business, and corporate solution videos.
